Evidence map›Paper›PMID 20485506›Full record

ArticlePloS one2010

Hepatitis C virus controls interferon production through PKR activation.

Noëlla Arnaud, Stéphanie Dabo, Patrick Maillard, Agata Budkowska, Katerina I Kalliampakou, Penelope Mavromara, Dominique Garcin, Jacques Hugon, Anne Gatignol, Daisuke Akazawa and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 117 citations in OpenAlex.

  1. Article
  2. Article
  3. Structural insights into the role of eIF3 in translation mediated by the HCV IRES.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. HCV-induced autophagy and innate immunity.Frontiers in immunology · 2024
    Review
  9. Article
  10. Review
  11. Article
  12. Inhibition of PKR by Viruses.Frontiers in microbiology · 2021
    Review
  13. Article
  14. Review
  15. LncRNAs in HCV Infection and HCV-Related Liver Disease.International journal of molecular sciences · 2020
    Review
  16. Review
  17. Altered mMolecular cell · 2020
    Article
  18. Article
  19. Review
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 5 countries.

Noëlla ArnaudInstitut Pasteur, Unité Hépacivirus et Immunité Innée, Paris, France.
Stéphanie Dabo
Patrick Maillard
Agata Budkowska
Katerina I Kalliampakou
Penelope Mavromara
Dominique Garcin
Jacques Hugon
Anne Gatignol
Daisuke Akazawa
Takaji Wakita
Eliane F Meurs
Institut Pasteur · FRNational Institute of Infectious Diseases · JPInstitut du Fer à Moulin · FRMcGill University · CAPasteur Hellenic Institute · GRUniversity of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis C virus is a poor inducer of interferon (IFN), although its structured viral RNA can bind the RNA helicase RIG-I, and activate the IFN-induction pathway. Low IFN induction has been attributed to HCV NS3/4A protease-mediated cleavage of the mitochondria-adapter MAVS. Here, we have investigated the early events of IFN induction upon HCV infection, using the cell-cultured HCV JFH1 strain and the new HCV-permissive hepatoma-derived Huh7.25.CD81 cell subclone. These cells depend on ectopic expression of the RIG-I ubiquitinating enzyme TRIM25 to induce IFN through the RIG-I/MAVS pathway. We observed induction of IFN during the first 12 hrs of HCV infection, after which a decline occurred which was more abrupt at the protein than at the RNA level, revealing a novel HCV-mediated control of IFN induction at the level of translation. The cellular protein kinase PKR is an important regulator of translation, through the phosphorylation of its substrate the eIF2alpha initiation factor. A comparison of the expression of luciferase placed under the control of an eIF2alpha-dependent (IRES(EMCV)) or independent (IRES(HCV)) RNA showed a specific HCV-mediated inhibition of eIF2alpha-dependent translation. We demonstrated that HCV infection triggers the phosphorylation of both PKR and eIF2alpha at 12 and 15 hrs post-infection. PKR silencing, as well as treatment with PKR pharmacological inhibitors, restored IFN induction in JFH1-infected cells, at least until 18 hrs post-infection, at which time a decrease in IFN expression could be attributed to NS3/4A-mediated MAVS cleavage. Importantly, both PKR silencing and PKR inhibitors led to inhibition of HCV yields in cells that express functional RIG-I/MAVS. In conclusion, here we provide the first evidence that HCV uses PKR to restrain its ability to induce IFN through the RIG-I/MAVS pathway. This opens up new possibilities to assay PKR chemical inhibitors for their potential to boost innate immunity in HCV infection.

Indexed as

Adaptor Proteins, Signal TransducingCell Line, TumoreIF-2 KinaseEnzyme ActivationEukaryotic Initiation Factor-2HepacivirusHepatitis CHumansInterferonsKineticsModels, ImmunologicalPhosphorylationProtein BiosynthesisProtein Kinase InhibitorsSubstrate SpecificityTime FactorsAdaptor Proteins, Signal TransducingeIF-2 KinaseEukaryotic Initiation Factor-2InterferonsMAVS protein, humanProtein Kinase InhibitorsTranscription FactorsTRIM25 protein, humanTripartite Motif ProteinsUbiquitin-Protein Ligases

Identifiers

PMID20485506
PMCPMC2868028
OpenAlexW1978216180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.